Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Refractory Advanced Melanoma”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Testing effectiveness (Phase 2)Study completedNCT04493203
What this trial is testing

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Who this might be right for
Advanced MelanomaUnresectable Melanoma
Yana Najjar 31
Testing effectiveness (Phase 2)WithdrawnNCT06030037
What this trial is testing

Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

Who this might be right for
PD-1 Refractory Advanced Melanoma
Diwakar Davar
Testing effectiveness (Phase 2)Study completedNCT04796194
What this trial is testing

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Who this might be right for
Advanced Melanoma
Lytix Biopharma AS 23
Early research (Phase 1)Active Not RecruitingNCT02298959
What this trial is testing

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Malignant Solid Neoplasm+12 more
National Cancer Institute (NCI) 59
Testing effectiveness (Phase 2)Study completedNCT04172454
What this trial is testing

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMelanoma
Akeso 68
Testing effectiveness (Phase 2)Ended earlyNCT03595683
What this trial is testing

Pembrolizumab and EDP1503 in Advanced Melanoma

Who this might be right for
Melanoma (Skin)Melanoma
University of Chicago 8
Early research (Phase 1)Ended earlyNCT04348916
What this trial is testing

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Who this might be right for
CancerMelanomaSolid Tumor+7 more
Oncorus, Inc. 66
Testing effectiveness (Phase 2)Study completedNCT03033576
What this trial is testing

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Melanoma of Unknown Primary+3 more
National Cancer Institute (NCI) 94
Testing effectiveness (Phase 2)WithdrawnNCT05561491
What this trial is testing

ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Who this might be right for
Melanoma
Targovax Oy
Testing effectiveness (Phase 2)Study completedNCT04577807
What this trial is testing

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Who this might be right for
Melanoma
Istari Oncology, Inc. 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05529316
What this trial is testing

Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Who this might be right for
Advanced Melanoma
Agenus Inc. 150
Testing effectiveness (Phase 2)Study completedNCT04526899
What this trial is testing

Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Who this might be right for
Melanoma Stage IIIMelanoma Stage IVUnresectable Melanoma
BioNTech SE 184
Testing effectiveness (Phase 2)Looking for participantsNCT06594991
What this trial is testing

Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Who this might be right for
Advanced Melanoma
Memorial Sloan Kettering Cancer Center 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT04971499
What this trial is testing

Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Who this might be right for
Melanoma
April Salama, M.D. 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07040436
What this trial is testing

Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

Who this might be right for
Advanced Melanoma
Oncodesign Precision Medicine 41
Early research (Phase 1)Ended earlyNCT05695898
What this trial is testing

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Who this might be right for
Metastatic MelanomaAdvanced Melanoma
University of California, San Francisco 6
Large-scale testing (Phase 3)Ended earlyNCT03445533
What this trial is testing

Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Who this might be right for
Metastatic Melanoma
Idera Pharmaceuticals, Inc. 481
Testing effectiveness (Phase 2)Looking for participantsNCT06425926
What this trial is testing

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Who this might be right for
Melanoma Stage IVSolid Tumor
Georgiamune Inc 117
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 25